Niflumic acid

Niflumic acid is a drug used for joint and muscular pain. It is categorized as an inhibitor of cyclooxygenase-2. In experimental biology, it has been employed to inhibit chloride channels.^[2] It has also been reported to act on GABA-A^[3] and NMDA channels^[4] and to block T-type calcium channels.^[5]

Niflumic acid
Clinical data

AHFS/Drugs.com	International Drug Names
ATC code	M01AX02 (WHO) M02AA17 (WHO)
Pharmacokinetic data
Elimination half-life	2.5 hr^[1]
Identifiers
IUPAC name 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid
CAS Number	4394-00-7^Y
PubChem CID	4488
IUPHAR/BPS	2439
ChemSpider	4333^N
UNII	4U5MP5IUD8
KEGG	D08275^Y
ChEMBL	ChEMBL63323^N
CompTox Dashboard (EPA)	DTXSID1023368
ECHA InfoCard	100.022.289
Chemical and physical data
Formula	C₁₃H₉F₃N₂O₂
Molar mass	282.222 g·mol⁻¹
3D model (JSmol)	Interactive image
Melting point	204 °C (399 °F)
SMILES C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
InChI InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)^N Key:JZFPYUNJRRFVQU-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

References

^ "Half life". Drug Bank. Retrieved 15 July 2011.

^ Knauf PA, Mann NA (May 1984). "Use of niflumic acid to determine the nature of the asymmetry of the human erythrocyte anion exchange system". The Journal of General Physiology. 83 (5): 703–25. doi:10.1085/jgp.83.5.703. PMC 2215658. PMID 6736917.

^ Sinkkonen ST, Mansikkamäki S, Möykkynen T, Lüddens H, Uusi-Oukari M, Korpi ER (September 2003). "Receptor subtype-dependent positive and negative modulation of GABA(A) receptor function by niflumic acid, a nonsteroidal anti-inflammatory drug". Molecular Pharmacology. 64 (3): 753–63. doi:10.1124/mol.64.3.753. PMID 12920213.

^ Lerma J, Martín del Río R (February 1992). "Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation". Molecular Pharmacology. 41 (2): 217–22. PMID 1371581.

^ Balderas E, Ateaga-Tlecuitl R, Rivera M, Gomora JC, Darszon A (June 2012). "Niflumic acid blocks native and recombinant T-type channels". Journal of Cellular Physiology. 227 (6): 2542–55. doi:10.1002/jcp.22992. PMC 4146346. PMID 21898399.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

Last edited on 3 December 2022,

at 18:13

Languages

●This page was last edited on 3

December 2022, at 18:13 (UTC).

●Content is available under CC B

Y-SA 4.0 unless otherwise noted.